TOPOIIα and HER-2/neu overexpression/amplification in Barrett's oesophagus, dysplasia and adenocarcinoma

Histopathology

Volumn 57, Issue 1, 2010, Pages 81-89

  Rossi, Elisa ^a   Villanacci, Vincenzo ^a   Bassotti, Gabrio ^b   Donato, Francesco ^a   Festa, Andrea ^a   Cengia, Gianpaolo ^c   Grisanti, Salvatore ^d   Cestari, Renzo ^c  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c SPEDALI CIVILI   (Italy)

^d Spedali Civili ^*  (Italy)

Author keywords

adenocarcinoma; Barrett's oesophagus; Her 2; TopoII

Indexed keywords

BIOLOGICAL MARKER; DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE 2ALPHA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; DNA TOPOISOMERASE II ALPHA; ERBB2 PROTEIN, HUMAN; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CANCER GRADING; CHROMOSOME 17; CHROMOSOME ABERRATION; CHROMOSOME ANEUSOMY; CLINICAL ARTICLE; CORRELATION ANALYSIS; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS DYSPLASIA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; ADENOCARCINOMA; ANEUPLOIDY; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; ESOPHAGUS TUMOR; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROTO ONCOGENE; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; ANTIGENS, NEOPLASM; BARRETT ESOPHAGUS; CHROMOSOMES, HUMAN, PAIR 17; DIAGNOSIS, DIFFERENTIAL; DNA TOPOISOMERASES, TYPE II, EUKARYOTIC; DNA-BINDING PROTEINS; ESOPHAGEAL NEOPLASMS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENES, ERBB-2; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES;

EID: 77954556405     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2010.03580.x     Document Type: Article

References (36)

1. Murphy AJ, Hughes CA, Barrett C et al. Low-level TOP2A amplification in prostate cancer is associated with HER2 duplication, androgen resistance, and decreased survival. Cancer Res. 2007 15 2893 2898.
2. Hansel DE, Ashfaq R, Rahman A et al. A subset of pancreatic adenocarcinomas demonstrates coamplification of topoisomerase IIalpha and HER2/neu: use of immunolabeling and multicolor FISH for potential patient screening and treatment. Am. J. Clin. Pathol. 2005 123 28 35.
3. Bouchalová K, Trojanec R, Kolár Z et al. Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer. Neoplasma 2006 53 393 401.
4. Kanta SY, Yamane T, Dobashi Y, Mitsui F, Kono K, Ooi A. Topoisomerase IIalpha gene amplification in gastric carcinomas: correlation with the HER2 gene. An immunohistochemical, immunoblotting, and multicolor fluorescence in situ hybridization study. Hum. Pathol. 2006 10 1333 1343.
5. Al-Kuraya K, Novotny H, Bavi P et al. HER2, TOP2A, CCND1, EGFR and C-MYC oncogene amplification in colorectal cancer. J. Clin. Pathol. 2007 60 768 772.
6. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998 16 413 428.
7. Brien TP, Odze RD, Sheehan CE, McKenna BJ, Ross JS. HER-2/neu gene amplification by FISH predicts poor survival in Barrett's esophagus-associated adenocarcinoma. Hum. Pathol. 2000 31 35 39. Erratum in: Hum. Pathol. 2000; 31; 524.
8. Isaacs RJ, Davies SL, Wells NJ, Harris AL. Topoisomerases II alpha and beta as therapy targets in breast cancer. Anticancer Drugs 1995 6 195 211.
9. Jarvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000 156 839 847.
10. Paik S, Bryant J, Tan-Chiu E et al. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J. Natl Cancer Inst. 2000 92 1991 1998.
11. Thor AD, Berry DA, Budman DR et al. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J. Natl Cancer Inst. 1998 90 1346 1360.
12. Lynch BJ, Guinee DG Jr., Holden JA. Human DNA topoisomerase II-alpha: a new marker of cell proliferation in invasive breast cancer. Hum. Pathol. 1997 28 1180 1188.
13. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 2002 8 1107 1116.
14. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 2002 8 1061 1067.
15. Mueller RE, Parkes RK, Andrulis I, O'Malley FP. Amplification of the TOP2A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004 39 288 297.
16. Paulson TG, Reid BJ. Focus on Barrett's esophagus and esophageal adenocarcinoma. Cancer Cell 2004 6 11 16.
17. DeMeester SR. Adenocarcinoma of the esophagus and cardia: a review of the disease and its treatment. Ann. Surg. Oncol. 2006 13 12 30.
18. Hamilton SR, Aaltonen LA. WHO pathology and genetics: tumors of digestive system.
19. Villanacci V, Rossi E, Zambelli C et al. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus. Dig. Liver Dis. 2007 39 305 311.
20. Villanacci V, Bellone G, Battaglia E et al. Ski/SnoN expression in the sequence metaplasia-dysplasia-adenocarcinoma of Barrett's esophagus. Hum. Pathol. 2008 39 403 409.
21. Ellis IO, Dowsett M, Bartlett J et al. Recommendations for HER2 testing in the UK. J. Clin. Pathol. 2000 53 890 892.
22. Dowsett M, Hanna WM, Kockx M et al. Standardization of HER2 testing: results of an international proficiency-testing ring study. Mod. Pathol. 2007 20 584 591.
23. McCarthy NJ, Yang X, Linnoila IR et al. Microvessel density, expression of estrogen receptor alpha, MIB-1, p53, and c-erbB-2 in inflammatory breast cancer. Clin. Cancer Res. 2002 8 3857 3862.
24. Mazurek A, Pierzyński P, Kuć P et al. Evaluation of angiogenesis, p-53 tissue protein expression and serum VEGF in patients with endometrial cancer. Neoplasma 2004 51 193 197.
25. Ishikawa T, Kobayashi M, Mai M, Suzuki T, Ooi A. Amplification of the c-erbB-2 (HER-2/neu) gene in gastric cancer cells. Detection by fluorescence in situ hybridization. Am. J. Pathol. 1997 151 761 768.
26. Walch A, Bink K, Gais P et al. Evaluation of c-erbB-2 overexpression and Her-2/neu gene copy number heterogeneity in Barrett's adenocarcinoma. Anal. Cell. Pathol. 2000 20 25 32.
27. Ellis IO, Bartlett J, Dowsett M et al. Best practice no 176: updated recommendations for HER2 testing in the UK. J. Clin. Pathol. 2004 57 233 237.
28. Brüderlein S, van der Bosch K, Schlag P, Schwab M. Cytogenetics and DNA amplification in colorectal cancers. Genes Chromosomes Cancer 1990 2 63 70.
29. Hicks DG, Yoder BJ, Pettay J et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum. Pathol. 2005 36 348 356.
30. Sabo E, Meitner PA, Tavares R et al. Expression analysis of Barrett's esophagus-associated high-grade dysplasia in laser capture microdissected archival tissue. Clin. Cancer Res. 2008 14 6440 6448.
31. Rauser S, Weis R, Braselmann H et al. Significance of HER2 low-level copy gain in Barrett's cancer: implications for fluorescence in situ hybridization testing in tissues. Clin. Cancer Res. 2007 13 5115 5123.
32. Rossi E, Grisanti S, Villanacci V et al. HER-2 overexpression/ amplification in Barrett's esophagus predicts early transition from dysplasia to adenocarcinoma: a clinico-pathologic study. J. Cell Mol. Med. 2009 13 3826 3833.
33. Wild CP, Hardie LJ. Reflux, Barrett's oesophagus and adenocarcinoma: burning questions. Nat. Rev. Cancer 2003 3 676 684.
34. Schottenfeld D, Beebe-Dimmer J. Chronic inflammation: a common and important factor in the pathogenesis of neoplasia. CA Cancer J. Clin. 2006 56 69 83.
35. Di Leo A, Isola J. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Clin. Breast Cancer 2003 4 179 186.
36. Villanacci V, Rossi E, Grisanti S et al. Targeted therapy with trastuzumab in dysplasia and adenocarcinoma arising in Barrett's esophagus: a translational approach. Minerva Gastroenterol. Dietol. 2008 54 347 353.